Adlai Nortye Limited - ADR

Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer.
Quotes
- Bid
- Ask
- Open
- Previous close
- Volume
- Relative volume
- High
- Low
Returns
Key stats
ESG risk
ESG risk is a measure of how well a company manages material ESG risks. Sustainalytics’ ESG risk category is designed to help investors identify and understand financially material ESG risks at the company level and how they might affect the long-term performance for equity investments. The scale is from 0-100. The lower the risk, the better (0 is equivalent to no risk and 100 the most severe).
Download ESG risk methodology (PDF)Financials
About Adlai Nortye Limited - ADR
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
Frequently asked questions
To buy Adlai Nortye Limited - ADR stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Adlai Nortye Limited - ADR by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Adlai Nortye Limited - ADR is ANL:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Adlai Nortye Limited - ADR has its primary listing on NASDAQ. You can trade Adlai Nortye Limited - ADR with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Adlai Nortye Limited - ADR is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Adlai Nortye Limited - ADR as part of a broader investment portfolio.